Related Experiment Video
Updated: May 14, 2026
13:47
Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
Published on: June 23, 2011
The Cellular Processing Capacity Limits the Amounts of Chimeric U7 snRNA Available for Antisense Delivery
Agathe Eckenfelder1, Julie Tordo, Arran Babbs
1Inserm U845, Hôpital Necker-Enfants Malades, Université Paris Descartes, Paris, France.
Molecular Therapy. Nucleic Acids
|January 25, 2013
Summary
Antisense oligoribonucleotides (AONs) linked to U7 small nuclear RNA (snRNA) improve exon skipping for genetic diseases like Duchenne muscular dystrophy (DMD). However, increased delivery may saturate cellular processing, creating by-products.
Area of Science:
- Molecular Biology
- Genetic Medicine
- RNA Therapeutics
Background:
- Genetic diseases often stem from pre-mRNA maturation defects, impacting splicing.
- Antisense oligoribonucleotides (AONs) offer a therapeutic strategy by modulating aberrant splicing.
- Current AON delivery methods face limitations in clinical translation due to vector dosage.
Purpose of the Study:
- To enhance the delivery and efficacy of U7 snRNA-based AONs for Duchenne muscular dystrophy (DMD).
- To investigate the impact of a muscle- and heart-specific enhancer (MHCK) on U7 snRNA shuttle expression and function.
- To identify potential limitations in cellular processing capacity when increasing therapeutic snRNA shuttle delivery.
Main Methods:
- Utilized a muscle- and heart-specific enhancer (MHCK) to drive U7 snRNA shuttle expression.
- Designed U7 snRNA shuttles carrying antisense sequences targeting human and murine DMD pre-mRNAs.
- Evaluated antisense delivery, exon skipping efficiency, and U7 snRNA by-product formation in vitro and in vivo.
Main Results:
- Improved delivery of U7 snRNA shuttles and enhanced exon skipping in both tissue culture and animal models.
- Observed the generation of aberrant U7 snRNA by-products, including 3' processed and unprocessed species.
- Identified potential cellular processing capacity saturation as a cause for by-product formation.
Conclusions:
- MHCK-driven U7 snRNA shuttles show promise for improving AON delivery and therapeutic effects in DMD.
- Cellular processing limitations must be considered for future strategies aiming to increase functional U7 shuttle delivery.
- Further research is needed to optimize snRNA shuttle production and overcome cellular constraints for effective gene therapy.
Related Concept Videos
02:30siRNA - Small Interfering RNAs
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
02:41Chromatin Structure Regulates pre-mRNA Processing
In eukaryotic cells, nascent mRNA transcripts need to undergo many post-transcriptional modifications to reach the cell cytoplasm and translate into functional proteins. For a long time, transcription and pre-mRNA processing were considered two independent events that occur sequentially in the cell. However, it has now been well established that transcription and pre-mRNA processing are two simultaneous processes that are precisely regulated inside the cell.
The chromatin structure, especially...
The chromatin structure, especially...
02:15Experimental RNAi
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
01:23RNA Interference
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
02:27Nonsense-mediated mRNA Decay
The Upf proteins that carry out nonsense-mediated decay (NMD) are found in all eukaryotic organisms, including humans. Each protein has an individual role, but they need to work in collaboration. Upf1 is an ATP-dependent RNA helicase that unwinds the RNA helix. Because Upf1 can unwind any RNA, Upf2 and Upf3 are required to help Upf1 discriminate between nonsense and normal mRNAs.
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...